home.aspx
 
EVENTS

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

AbbVie

At AbbVie, we believe the world needs new approaches to addressing today’s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people’s lives.

RELATED NEWS


AbbVie and Harpoon Therapeutics have announced that the former will has licensed the B cell maturation antigen (BCMA)-targeting drug HPN217 for multiple myeloma from the pair’s drug discovery collaboration. AbbVie and Harpoon entered into a drug discovery collaboration in October 2017 to leverage the latter’s Tri-specific T cell Activating Construct (TriTAC) technology to discover T cell-focused immuno-oncology drugs. Financial terms of this collaboration were not publicly disclosed ...

READ MORE

US-based Dragonfly Therapeutics has announced it has signed a multi-target collaboration with AbbVie to advance immunotherapies created using its Tri-specific Natural Killer (NK) cell engager Therapies (TriNKET) technology for autoimmune and oncology indications. AbbVie has made an undisclosed upfront payment to Dragonfly, and has agreed to future success-based milestone and royalty payments. As a result of the agreement, AbbVie will have the option to license exclusive, global rights to develop...

READ MORE

AbbVie has received the US Food and Drug Administration (FDA) approval for Mavyret (glecaprevir / pibrentasvir) to lower the therapy period from 12 to eight weeks in hepatitis C (HCV) patients with cirrhosis. The indication for once-daily therapy is meant for treatment-naïve, compensated cirrhotic, chronic HCV patients across all genotypes (GT1-6). Previously, the drug secured FDA approval in August 2017 for eight-week, pan-genotypic therapy for treatment-naïve HCV patients without cir...

READ MORE

Pharma watchers have been awaiting House Speaker Nancy Pelosi’s drug pricing plan, and on Monday the industry got a peek at what Democrats are discussing to lower drug prices. The upshot? If the House leadership gets its way, it would devastate pharma's pricing power. The leaked document is outdated and the proposals could change, a senior aide told The Hill. The industry would put up fierce opposition, and Republicans could well balk, too. But the bullet points offer a glimpse into th...

READ MORE

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far. As it searched for new drugs to replace revenues lost from the patent expiry of its mega-blockbuster Humira, AbbVie snapped up Rova-T’s developer Stemcentrx in 2016 for $5.8 billion. But the gamble has not paid off after yet another trial disaster from the antibody-drug conjugate, full name rovalpituzumab tesirine. A...

READ MORE

AbbVie has announced the US Food and Drug Administration FDA approval of Rinvoq upadacitinib for moderate to severe active rheumatoid arthritis RA. In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis, and significantly inhibited radiographic progression even without methotrexate. The study was one of the largest registrational Phase III programs in RA with approximately...

READ MORE

Lawmakers may have left the nations capital for summer vacation, but regulators at the FDA are staying busy. The agency churned out five approvals just last week from companies large and small and five more decisions are due by months end. Three of last weeks green lights opened the way for launches worth half a billion or more in annual sales. But the week started with a couple of OKs smaller on the sales side, if still significant for the organizations that developed them. Pretomanid, a tuberc...

READ MORE

Allergan has confirmed it will hive off two drugs so that AbbVies 63 billion dollars takeover offer could pass U.S. antitrust scrutiny. But recent regulatory decision and indecision on pharma deals has analysts worried whether that would be enough. In an investor Q and A published Tuesday, Allergan said it will sell brazikumab and Zenpep as part of the merger process, “irrespective of whether such divestitures are required by the regulators.” Those two have been suspected for-sale ta...

READ MORE

The Pharma industry cheered when the Trump administration introduced a proposal putting drug pricing rebates in the crosshairs. But like so many other drug pricing ideas over the years, the measure didnt go anywhere. Now, the administration is switching gears to importation. HHS on Wednesday presented a plan for bringing in cheaper drugs from Canada, an approach the industry staunchly opposes. It marks a major shift from previous policies on imports, but the plan itself might not do much to lowe...

READ MORE

With long time immunology blockbuster Humira on the decline, AbbVie is looking to next-gen competitor Skyrizi to chip in. A nod from England's cost watchdog could help. The National Institute for Health and Care Excellence (NICE) recommended (PDF) Skyrizi as a second-line treatment for severe plaque psoriasis in adults who've failed on conventional treatments such as ciclosporin, methoxotrate and phototherapy. In its final appraisal, NICE said second-line Skyrizi was more effective for p...

READ MORE

EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Drug Formulation & Analytical Techniques
DRUG FORMULATION & ANALYTICAL TECHNIQUES
December 16-17, 2019
Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally...